Evidence map›Paper›PMID 34346556›Full record

ArticleAngewandte Chemie (International ed. in English)2021

Asymmetric Cation-Olefin Monocyclization by Engineered Squalene-Hopene Cyclases.

Michael Eichenberger, Sean Hüppi, David Patsch, Natalie Aeberli, Raphael Berweger, Sandro Dossenbach, Eric Eichhorn, Felix Flachsmann, Lucas Hortencio, Francis Voirol and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 23 citations in OpenAlex.

  1. Catalytic Asymmetric Cationic Geranyl Cyclizations.Journal of the American Chemical Society · 2026
    Article
  2. A tailored CoA ligase-Nature catalysis · 2026
    Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Asymmetric Cation-Olefin Monocyclization by Engineered Squalene-Hopene Cyclases.Angewandte Chemie (International ed. in English) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Michael EichenbergerZurich University of Applied Sciences, Life Sciences and Facility Management, Einsiedlerstrasse 31, 8820, Wädenswil, Switzerland.ORCID 0000-0003-4749-4135
Sean HüppiZurich University of Applied Sciences, Life Sciences and Facility Management, Einsiedlerstrasse 31, 8820, Wädenswil, Switzerland.
David PatschZurich University of Applied Sciences, Life Sciences and Facility Management, Einsiedlerstrasse 31, 8820, Wädenswil, Switzerland.
Natalie AeberliFragrances S&T, Ingredients Research, Givaudan Schweiz AG, Kemptpark 50, 8310, Kemptthal, Switzerland.
Raphael BerwegerFragrances S&T, Ingredients Research, Givaudan Schweiz AG, Kemptpark 50, 8310, Kemptthal, Switzerland.
Sandro DossenbachFragrances S&T, Ingredients Research, Givaudan Schweiz AG, Kemptpark 50, 8310, Kemptthal, Switzerland.
Eric EichhornFragrances S&T, Ingredients Research, Givaudan Schweiz AG, Kemptpark 50, 8310, Kemptthal, Switzerland.ORCID 0000-0003-2113-6305
Felix FlachsmannFragrances S&T, Ingredients Research, Givaudan Schweiz AG, Kemptpark 50, 8310, Kemptthal, Switzerland.
Lucas HortencioFragrances S&T, Ingredients Research, Givaudan Schweiz AG, Kemptpark 50, 8310, Kemptthal, Switzerland.
Francis VoirolFragrances S&T, Ingredients Research, Givaudan Schweiz AG, Kemptpark 50, 8310, Kemptthal, Switzerland.
Sabine VollenweiderScience & Technology, Givaudan International SA, Kemptpark 50, 8310, Kemptthal, Switzerland.
Uwe T BornscheuerInstitute of Biochemistry, Dept. of Biotechnology & Enzyme Catalysis, Greifswald University, Felix-Hausdorff-Strasse 4, 17487, Greifswald, Germany.ORCID 0000-0003-0685-2696
Rebecca BullerZurich University of Applied Sciences, Life Sciences and Facility Management, Einsiedlerstrasse 31, 8820, Wädenswil, Switzerland.ORCID 0000-0002-5997-1616
Givaudan (Switzerland) · CHZHAW Zurich University of Applied Sciences · CHUniversität Greifswald · DE

Funding

national center of competence in research - catalysis / SNFstaatssekretariat für bildung, forschung und innovation PgB 2017 - 2020: P - 14
6 · The paper itself

Abstract

Squalene-hopene cyclases (SHCs) have great potential for the industrial synthesis of enantiopure cyclic terpenoids. A limitation of SHC catalysis has been the enzymes' strict (S)-enantioselectivity at the stereocenter formed after the first cyclization step. To gain enantio-complementary access to valuable monocyclic terpenoids, an SHC-wild-type library including 18 novel homologs was set up. A previously not described SHC (AciSHC) was found to synthesize small amounts of monocyclic (R)-γ-dihydroionone from (E/Z)-geranylacetone. Using enzyme and process optimization, the conversion to the desired product was increased to 79 %. Notably, analyzed AciSHC variants could finely differentiate between the geometric geranylacetone isomers: While the (Z)-isomer yielded the desired monocyclic (R)-γ-dihydroionone (>99 % ee), the (E)-isomer was converted to the (S,S)-bicyclic ether (>95 % ee). Applying the knowledge gained from the observed stereodivergent and enantioselective transformations to an additional SHC-substrate pair, access to the complementary (S)-γ-dihydroionone (>99.9 % ee) could be obtained.

Indexed as

chemoenzymatic synthesiscyclizationprotein engineeringsqualene-hopene cyclasessubstrate engineering

Identifiers

PMID34346556
PMCPMC9290348
OpenAlexW3188784386

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.